You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A Noninvasive Platform to Assess Maternal Risk for Perinatal Complications in the First Trimester

    SBC: Cradle Genomics, Inc.            Topic: NICHD

    Limited information is available about early human placentation when many pregnancy pathologies originateTo address this knowledge gap and begin development of robust diagnostic tool to manage pregnancy complicationswe propose a pilot study based on a highly sensitive immune assay and our company s base technologyTrophoblast Retrieval and Isolation from the CervixTRICTRIC uses a Pap smearconsidere ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss

    SBC: NANOMEDIC, INC.            Topic: NIA

    AbstractIn this SBIR Phase I applicationour goal is to demonstrate proof of concept of our lead chelating agent as a potential therapeutic for the prevention of osteoporosis induced by aromatase inhibitorAItherapy in postmenopausal women with hormone receptor positive breast cancerAlthough AI therapy shows great improvements in cancer free and overall survivalits treated patients face a risk of os ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons

    SBC: Axonova Medical LLC            Topic: NINDS

    ABSTRACT Peripheral nerve injuryPNIis a common consequence of trauma or surgeryand the extent of functional recovery is often unsatisfactoryMoreovera particular challenge is the repair ofmajorPNIdefined as injuries where a large segment of a nerve is losti eandgtcmor more proximal injuriese gbrachial plexus or upper armthat necessitate extremely long distances for axonal regeneration to distal end ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    Idiopathic pulmonary fibrosisIPFis the most common and severe fibrotic lung disease in older adults and lacks any highly effective therapyEmerging evidence indicates that loss of proteostasis in the alveolar epithelium contributes to the pathogenesis of IPF and several other fibrotic pulmonary conditionsIn recent workwe uncovered that treating mice with a dual Liver X Receptor alpha betaLXRagonist ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Heart-health Networking App to help persons returning from incarceration manage cardiovascular disease

    SBC: Starship Health Technologies, LLC            Topic: NHLBI

    We propose to develop a mobile health smartphone applicationappcalled the HEart health Networking AidHENAto help persons returning from incarceration into open societyHENA will help them manage cardiovascular diseaseCVDduring their re integration periodand in the broader context of other health and non health related challenges they faceMore thenpersons are released each year from state and federa ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Partelligence

    SBC: OPTOFLUIDICS, INC.            Topic: 400

    Abstract Halo Labs proposes to developPartelligencea particle ID technique that enables accurate and rapid identification of contaminating particles in biopharmaceutical formulationsProtein therapeutics currently represent betweenandof the overall pharmaceutical marketThe primary concern for this class of therapeutics is that they can elicit an immune response from patients who develop antidrug an ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    Abstract Aoligomers are considered the most toxic structural form of Amyloid betacausing synaptotoxic changes underlying cognitive decline in Alzheimer s diseaseCogRx has developed the world s first highly brain penetrant drug that selectively displaces oligomers from synaptic receptor sites and clears oligomers from the brain into the cerebrospinal fluidCSFThis first in class drugCTallosterically ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Daily and localized NSAID sonophoresis for symptomatic treatment of knee osteoarthritis

    SBC: Zetroz Systems LLC            Topic: NIA

    Project SummaryOsteoarthritisOAis the most common type of arthritisaffecting overmillion adults in the United States inand represents overof medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of HealthOverof individuals overhave symptomatic OA and reduced mobility due to the diseaseOA pain is often mitigated with conservative treatment app ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Visible light activated implant devices to prevent biofilm formation

    SBC: Sonata LLC            Topic: NCEZID

    Prevention of biofilms on invasive medical devices has the potential to significantly reduce hospital acquired infections and improve patient outcomesProsthetic joint infectionsPJIsacquired from orthopedic implantsoften the result of microorganism contamination on the implant surface during surgeryaffect patient recoveries and can lead to significant mortalitiesOne approach for reducing the incide ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  10. A Rapid Multiplexed Assay for the Diagnosis of Viral Hepatitis at the Point of Care

    SBC: Instadiagnostics Inc.            Topic: NCHHSTP

    Abstract InstadiagnosticsIDIis developing a point of carePOCdiagnostic technology platform with the goal of providing early detectionscreeningand treatment monitoring for patients at primary care centerscommunity clinicsurgent care centersand emergency departmentsThe device consists of a portable readerthe InstaReaderand disposable cartridgesInstaCartridgeA range of disease specific cartridges wil ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
US Flag An Official Website of the United States Government